Botulinum toxin for lower limb spasticity in children with cerebral palsy: A single-blinded trial comparing dilution techniques

American Journal of Physical Medicine and Rehabilitation

Volumn 83, Issue 10, 2004, Pages 766-773

  Lee, Li Rong ^a   Chuang, Yao Chia ^a   Yang, Baii Jia ^a   Hsu, Min Jung ^a   Liu, Ying Hung ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Botulinum Toxin; Cerebral Palsy; Dilution Volume; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; INJECTION PAIN; LEG; MALE; MUSCLE ACTION POTENTIAL; SINGLE BLIND PROCEDURE; SPASTICITY; ACTION POTENTIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ACTION POTENTIALS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEG; MALE; MUSCLE SPASTICITY; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 4944247979     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PHM.0000137314.38806.95     Document Type: Article

References (30)

1. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-9
2. Cosgrove AP, Graham HK: Botulinum toxin A in the management of children with cerebral palsy. J Bone Joint Surg 1992;74(suppl):135-6
3. Bhakta BB, Cozens JA, Bamford JM, et al: Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5
4. Snow BJ, Tsui KC, Bhatt MH, et al: Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990;28:512-5
5. Yablon SA, Agana BT, Ivanhoe CB, et al: Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open-labeled trial. Neurology 1996;47:939-44
6. Lang AM: Botulinum toxin type A therapy in chronic pain disorder. Arch Phys Med Rehabil 2003;84(suppl 1):69-73
7. Green P, Fahn S, Diamond B, et al: Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-7
8. Wong V: Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 1998;18:124-31
9. Koman LA, Mooney JF, Smith P, et al: Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20:108-15
10. Yang TF, Fu CP, Kao NT, et al: Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003;82:284-9
11. Sutherland DH, Kaufman KR, Wyatt MP, et al: Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999;10:1-9
12. Gracies JM, Weisz DJ, Yang BY, et al: Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol 2002;52:S87
13. Hesse S, Jahnke MT, Luecke D, et al: Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40
14. Kim HS, Hwang JH, Jeong ST, et al: Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-6
15. Cosgrove AP, Corry IS, Graham HK: Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-96
16. Reiter F, Danni M, Lagalla G, et al: Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998;79:532-5
17. Shaari CM, Sanders I: Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-9
18. Francisco GE, Boake C, Vaughn A: Botulinum toxin in upper limb spasticity after acquired brain injury: A randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-63
19. Palisano R, Rosenbaum P, Walter S, et al: Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-23
20. Russman BS, Tilton A, Gormley ME Jr: Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve 1997;6:S181-93
21. Bakheit AMO: Botulinum Toxin Treatment of Muscle Spasticity. Dublin, Blackhall, 2001, pp 128-9
22. Pierson SH, Katz DI, Tarsy D: Botulinum toxin A in the treatment of spasticity: Functional implications and patient selection. Arch Phys Med Rehabil 1996;77:717-21
23. Slawek J, Klimont L: Functional improvement in cerebral palsy patients treated with botulinum toxin A injections: Preliminary results. Eur J Neurol 2003;10:313-7
24. Dressler D, Rothwell JC: Electromyographic quantification of the paralyzing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 2000; 43:13-6
25. Eleopra R, Tugnoli V, Grandis DD: The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in human. Mov Disord 1997;12:89-94
26. Shin HI, Han TR, Seo KI, et al: Effects of dilution volume of botulinum toxin A (abstract). J Korean Acad Phys Med Rehabil 2000;28:67
27. Boyd RN, Graham HK: Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6:S23-36
28. Olney RK, Aminoff MJ, Gelb DJ, et al: Neuromuscular effects distant from the site of botulinum neurotoxin injections. Neurology 1988;38:1780-3
29. Dutton JJ: Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short and long-term local and systemic effects. Surv Ophthalmol 1996; 41:51-65
30. Fertl E, Schnider P, Schneider B, et al: Remote effects of chronic botulinum toxin treatment: Electrophysiologic results do not indicate subclinical remodeling of non injected muscles. Eur Neurol 2000;44:139-43